![]() Ezetimibe (top) and rosuvastatin (bottom) | |
Combination of | |
---|---|
Ezetimibe | Hypolipidemic agent |
Rosuvastatin | Statin |
Clinical data | |
Trade names | Ridutrin,Cholerose Plus, Lipocomb, Rosuzet, others [1] [2] |
AHFS/ Drugs.com | Multum Consumer Information |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [6] [7] In some countries it is sold as a kit or a pack containing two distinct pills. [8] [1]
The combination was approved for medical use in the United States in March 2021. [5]
Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. [9]
Ezetimibe/rosuvastatin combines two lipid-lowering therapies with distinct actions to achieve greater lowering of LDL-C that either agent alone.
Together, these drugs cause a net decrease in hepatocyte intracellular cholesterol leading to scavenging of LDL particles from the blood via upregulation of the LDL receptor.
![]() Ezetimibe (top) and rosuvastatin (bottom) | |
Combination of | |
---|---|
Ezetimibe | Hypolipidemic agent |
Rosuvastatin | Statin |
Clinical data | |
Trade names | Ridutrin,Cholerose Plus, Lipocomb, Rosuzet, others [1] [2] |
AHFS/ Drugs.com | Multum Consumer Information |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [6] [7] In some countries it is sold as a kit or a pack containing two distinct pills. [8] [1]
The combination was approved for medical use in the United States in March 2021. [5]
Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. [9]
Ezetimibe/rosuvastatin combines two lipid-lowering therapies with distinct actions to achieve greater lowering of LDL-C that either agent alone.
Together, these drugs cause a net decrease in hepatocyte intracellular cholesterol leading to scavenging of LDL particles from the blood via upregulation of the LDL receptor.